Press Release FeedGet the RSS feed
Menu

PR Newswire

Csquare, Inc. Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Csquare, Inc. (CSQR)

PR Newswire

Of the $356.0 million in "available liquidity" Csquare reported for June 30, 2026, $209.5 million was restricted cash that its own filing described as unavailable for general corporate use. CSQR shareholders now face losses after an October 22 short report. Csquare, Inc. (NYSE: CSQR ) reported $356.0 million of "available liquidity" in August. Today, October 22, 2026, CSQR shares fell after a Dalrymple Finance short report alleged the Company faces projected 2026 cash shortfalls. If you bought CSQR and lost money, you may have legal rights, and time matters. Investors who suffered losses are encouraged to submit their loss information for review . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. Csquare filed its Form 10-Q for the quarter ended June 30, 2026, on August 10, 2026. The filing reported "$356.0 million of available liquidity." Inside that figure was $209.5 million of trustee-controlled restricted cash. The same filing stated that this cash is "not available for general corporate use." Unrestricted cash came to approximately $120.8 million. Keith Dalrymple of Dalrymple Finance published the October 22 report on DF Research Substack. The report alleged projected 2026 cash shortfalls at Csquare. Levi & Korsinsky is investigating potential securities law violations concerning how the Company presented its available liquidity to investors. Lost money on CSQR? Request a free review of your losses or call Joseph E. Levi, Esq. at (212) 363-7500. Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered. Frequently Asked Questions About the CSQR Investigation Q: What is the CSQR securities fraud investigation about? A: A securities investigation is pending concerning Csquare, Inc. (NYSE: CSQR ) regarding potentially materially false or misleading statements. Shares fell on October 22, 2026, after a Dalrymple Finance short report alleged projected 2026 cash shortfalls at the Company, causing losses for shareholders. Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Csquare, Inc. made materially false or misleading statements regarding its available liquidity. This includes the $356.0 million figure in its Q2 2026 Form 10-Q, which included $209.5 million of restricted cash. CSQR shares fell after a short report alleging projected 2026 cash shortfalls was published on October 22, 2026. Q: When did Csquare allegedly mislead investors? A: The investigation concerns statements made before the October 22, 2026 short report that allegedly caused investors to purchase CSQR securities at inflated prices. Q: What do CSQR investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation. Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices. Q: What if I already sold my CSQR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CSQR and sold at a loss may still participate in the investigation. Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval. Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 Attorney Advertising. Prior results do not guarantee similar outcomes. SOURCE Levi & Korsinsky, LLP

  1. Denarius Metals Corp.DENARIUS METALS FILES TORAL PROJECT TECHNICAL REPORT ON SEDAR+Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or "the Company") announced today the filing of a National Instrument 43-101 – Standards of Disclosure for Mineral Projects compliant technical report in support of the Mineral...
  2. SustainabilityNEXT Properties (Trust 2401)NEXT PROPERTIES ANNOUNCES RESULTS OF EXCHANGE OFFERS FOR ANY & ALL OF ITS OUTSTANDING 6.950% SENIOR NOTES DUE 2044 AND 6.390% SENIOR NOTES DUE 2050 FOR ADDITIONAL 7.731% SENIOR SUSTAINABILITY-LINKED NOTES DUE 2056NEXT Properties (Trust 2401), a trust formed under the laws of the United Mexican States (the "Trust" or "NEXT Properties"), today announced the expiration date results of its offers to exchange (collectively, the "Exchange Offers") any and all...
  3. LEAP GroupLEAP Group Relaunches HumanView, a Growth Intelligence System Built to Explain Why Customers Behave the Way They DoReimagined from the ground up, HumanView pairs statistical modeling with expert analysts to turn millions of real-world customer signals into business decisions — LEAP Group today announced the relaunch of HumanView, its growth intelligence...
  4. EducationLevi & Korsinsky, LLPSLM Corporation Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into SLM Corporation (SLM)SLM shares fell after the student lender disclosed it had paused most of its third-party recovery activities as third-quarter net charge-offs reached $90.4 million. Levi & Korsinsky is investigating potential securities law violations on behalf of SLM investors. NEW YORK, Oct. 23, 2026...
  5. FinanceLevi & Korsinsky, LLPGentex Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Gentex (GNTX)Gentex lowered its 2026 revenue guidance to approximately $2.65 billion, down from a prior range of $2.65 billion to $2.75 billion. Shareholders holding losses may have rights worth reviewing now. — The high end of Gentex Corporation's (NASDAQ: GNTX)...
  6. HealthcarePathalys PharmaPathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial...